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Preventing initiation of tobacco product use,
promoting cessation of tobacco use, and protecting
the public from exposure to second hand smoke are
recognised by the World Health organization
(WHO) Framework Convention on Tobacco
Control (FCTC) and by the WHO Study Group
on Tobacco Product Regulation (TobReg) as the
most effective approaches to reducing tobacco
related morbidity and mortality. However, the
FCTC also recognises the need for tobacco product
regulation in articles 9 and 10 of the treaty. In
order to inform that process TobReg has developed
a series of reports that begin to provide a scientific
foundation for tobacco product regulation.
1–6 This
paper summarises a proposal, and the considera-
tions that led to it, developed by a joint
International Agency for Research on Cancer
(IARC) and WHO working group, and approved
by TobReg, which presents performance standards
for cigarettes and a strategy to use them to
mandate a reduction in the toxicant yields for
cigarette smoke.
WHY A NEW APPROACH WAS NECESSARY AND
OTHER APPROACHES CONSIDERED
The most common measurements used historically
to categorise cigarette smoke have been machine
measured tar, nicotine and carbon monoxide
(TNCO) yields per cigarette based on the US
Federal Trade Commission (FTC)/International
Standards Organization (ISO) testing regimen.
There is a current scientific consensus that these
per cigarette yields do not provide valid estimates
of human exposure or of relative human exposure
when smoking different brands of cigarettes.
1 7–9
Communication of these measures to smokers as
estimates of their exposure or risk creates harm by
misleading smokers to believe that differences in
exposures and risk are likely to occur with switch-
ing to cigarette brands with different machine-
measured yields. This ongoing harm precludes
continued acceptance of current regulatory strate-
gies based on per cigarette machine measured
TNCO levels and necessitates development of
new regulatory approaches.
Machine smoking regimens other than the FTC/
ISO regimen have also been examined, particularly
ones with more intense puffing parameters and
which block some or all of the ventilation holes in
cigarette filters. Examples include those developed
by the US State of Massachusetts and the
Canadian Government. These regimens generally
produce higher yields per cigarette and reduce the
differences between brands in the yields.
Nevertheless, these regimens continue to maintain
a ranking of brands by tar and nicotine yield per
cigarette, and the rankings by yield per cigarette
using these more intense regimens also do not
provide valid estimates of human exposure, or of
the relative exposure, experienced by smokers
when they smoke different brands of cigarettes.
A single machine testing regimen produces a single
set of toxicant yields. In contrast to the machine,
individual smokers vary the puffing pattern with
which they smoke different cigarettes of the same
brand, and cigarette design changes can lead
smokers to systematically change how they puff
cigarettes. Thus, even yields using these more
intense smoking regimens have the potential to
mislead smokers when expressed per cigarette and
the machine measured yields should not be used to
support claims of reduced exposure or risk.
These limitations of machine measurements led
to efforts to quantify actual human exposures in
smokers by measuring biomarkers in blood, urine,
and saliva. However, since these biomarkers are
measured in human smokers they are influenced
by characteristics of the individual, characteristics
of the individual’s smoking behaviour, as well as by
characteristics of the product smoked.
28
Distinguishing the differences in biomarker levels
due to variations between products from the
differences due to smoker behaviour (eg who uses
the product and how they use it), is a formidable
scientific challenge. Research is needed to resolve
these issues in order to allow exposure biomarkers
to become an effective tool for product regulation.
The multiplicity of brands on the market, self
selection of smokers who use different products,
and differences in how smokers of different
products use them, make the use of biomarkers
of exposure in a regulatory strategy to monitor
cigarette product differences problematic given the
current level of scientific knowledge.
Characterisation of the differences in harm
caused by different cigarettes would offer a power-
ful metric for product regulation. Markers of
biologically effective dose (levels of toxicants in
critical target organs or tissues) are likely to be
developed and validated in the future, and they are
expected to offer more precise measures of smoke
uptake and better predictions of smoke toxicity.
7
Measures of injury or biomarkers of disease risk are
also likely to be validated in the future. They will
allow more rapid assessment of differences in
disease risks than is currently available from
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advances may allow assessment of differences in risk between
tobacco products in the future. Nevertheless, at this moment,
none of these measures have been validated as reliable
independent predictors of differences in tobacco related disease
risk among smokers using different products.
10
The limitations of measures of human exposure and human
injury suggest that, for the near future, product regulatory
approaches may be limited to measures of the differences
between products in design characteristics, contents and
emissions rather than measures derived from their human use.
It is generally assumed that product design characteristics,
constituents and additives contribute to the toxicity of
cigarettes, the addictiveness of the product and the likelihood
that new smokers will start or confirmed smokers will quit.
TobReg has examined the evidence supporting these assump-
tions and concluded that further research is likely to provide
compelling evidence to establish these assumptions as true.
45
Nevertheless, the existing science base is currently not sufficient
to allow regulation of these characteristics based on their effects
on toxicity of the product either by establishing product
performance standards or by prohibiting the use of specific
design features or constituents.
45In addition, TobReg felt that
regulation of the end product of tobacco combustion (emis-
sions) might be a more robust tool for assessing product
performance than changes in individual design features or
components, particularly given the limited understanding of the
interaction cigarette design features and components have in
influencing smoke toxicity.
These reviews led TobReg to the conclusion that chemical
measurements of the smoke produced by machines, and their
use as inputs for product hazard assessment, with all of their
limitations, may be the limit of current scientific assessment of
differences between brands that can be used for regulatory
assessment of product toxicity. This conclusion is limited to
product toxicity regulation and is not intended to preclude
regulation or prohibition of products with specific characteristic
that have other important public health effects, for example
candy flavoured cigarettes or reduced ignition propensity
cigarettes.
THE PROPOSED APPROACH FOR MANDATED LOWERING OF
TOXICANT LEVELS
TobReg recommends a strategy for regulation based on product
performance measures with the goal of reducing toxicant levels
in mainstream cigarette smoke measured under standardised
conditions.
56 It recommends establishing levels for selected
toxicants per mg nicotine and prohibiting the sale or import of
cigarette brands that have yields above these levels. The purpose
of normalising toxicant levels per mg nicotine is to shift the
interpretation of the measurement away from the quantity of
the smoke generated per cigarette, and away from the
misleading use of TNCO values as measures of human exposure
and risk. It moves towards product characterisation of smoke
toxicity generated under standardised conditions. The toxicants
currently recommended for mandated reductions by TobReg
and proposed levels are presented in table 1.
Available data on the variation in the toxicant levels for
cigarette brands provided an initial set of observations used to
identify levels of reduction that have already been achieved by
some products on the existing market. The initial levels
suggested for regulating tobacco specific nitrosamines (NNK
(4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) and NNN
(N9-nitrosonornicotine)) are the median values for the brands
on the market, and for seven additional toxicants the levels
recommended are set at 125% of the median value of the
toxicant per mg nicotine for the brands on the market being
regulated. These initial levels are intended to be a first step in an
overall strategy to further reduce levels of toxicants in tobacco
smoke as our understanding of what is possible expands and
new technology develops. The levels recommended by TobReg
reflect a judgment from available data as to the most practical
trade-off considering the need to regulate a range of toxicants,
to mandate substantive lowering of those toxicants, and yet not
to require elimination of most of the brands. Regulators are
encouraged to obtain data from their own markets and of
course may select different levels more appropriate for their
own circumstances. The specific quantitative values recom-
mended for the nine toxicants are derived from an international
sample of Philip Morris (American blended cigarettes) and
Canadian Brands (predominantly flue cured brands) to allow
selection of values for the type of cigarette used in a market, and
to help guide regulators who choose not to examine the
variation in their own markets.
The recommendation is to implement the policy change in
phases beginning with a period of required annual reporting of
toxicant levels by cigarette manufacturers to the regulatory
authority. This should be followed by the promulgation of the
levels for toxicants above which brands cannot be offered for
sale. Finally, the established levels would be enforced. It is
expected that regulators will take additional actions to further
reduce the mandated levels of toxicants as this regulatory
strategy is fully implemented. These actions can be in the form
Table 1 Toxicants recommended for mandated lowering
Toxicant
Level in mg/mg nicotine
(international brands)*
Level in mg/mg nicotine
(Canadian brands){ Criteria for selecting the value
NNK 0.072 0.047 Median value of the data set
NNN 0.114 0.027 Median value of the data set
Acetaldehyde 860 670 125% of the median value of the data set
Acrolein 83 97 125% of the median value of the data set
Benzene 48 50 125% of the median value of the data set
Benzo[a]pyrene 0.011 0.011 125% of the median value of the data set
1,3-Butadiene 67 53 125% of the median value of the data set
Carbon monoxide 18 400 15 400 125% of the median value of the data set
Formaldehyde 47 97 125% of the median value of the data set
*Based on data from Counts et al.
11
{Based on the data reported to Health Canada minus the brands with NNN/mg nicotine levels over 0.1, which eliminates most US and Gauloise brands (http://www.hc-sc.gc.ca/hl-
vs/tobac-tabac/legislation/reg/indust/constitu_e.html).
12
NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NNN, N9-nitrosonornicotine.
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achievable with new technology or product designs.
Prohibiting consumer communications based on any machine
measurements is a necessary condition of this strategy. Given
the limitations of existing science, regulatory authorities have
an obligation to ensure that the public is not misled by the
results of the recommended machine testing and mandated
lowering regulatory strategy, as the public was misled by the
use of machine testing for tar and nicotine yields.
SELECTION OF THE MACHINE SMOKING REGIMEN
Normalisation of the machine generated yields per mg nicotine,
or per mg tar, does not eliminate the variation in the values
measured by the different machine regimens. Figure 1 presents
the values for toxicants in a data set of international Philip
Morris brands measured with the standard ISO, the intense
modified ISO used by Health Canada, and the Massachusetts
Department of Public Health regimens. The data are presented
as the ratio of the latter two regimens to the values derived
using the standard ISO/FTC regimen. The differences in the
yields of these toxicants per mg nicotine with these different
regimens likely reflect differences in temperature of combustion,
rates of air flow at the point of combustion and other factors
that result from the differences in puff profiles used.
While these data demonstrate that full characterisation of the
composition of the smoke generated by different brands of
cigarettes would likely require a wide range of puff profiles, a
performance standard is not intended to be a complete
characterisation of the smoke but rather a standardised measure
to allow regulatory comparison across brands in their perfor-
mance under standardised conditions.
Performance standards could be set based on any machine
regimen, but TobReg felt that recommending one regimen
would reduce regulatory costs and promote international
comparisons. All machine measurement regimens have limita-
tions and no one regimen is ideal; but in considering the three
regimens for which there are substantial regulatory and
laboratory experience, the intense smoking regimen used by
Health Canada was selected as having the best balance of
advantages and limitations. This selection was based on several
criteria. First, the larger quantity of smoke generated by this
regimen reduces the coefficient of variation (CV) of the replicate
measurements for some of the toxicants measured. Second,
with certain design features the more intense machine
parameters may yield levels of individual smoke toxicants
substantially above those that would result with the ISO
regimen. Third, the toxicants are generated under conditions of
combustion that correspond to a more intense human smoking
profile and therefore may better reflect how the product
performs under these intense conditions. And fourth, the
Canadian intense regimen may more accurately characterise
cigarette design characteristics, such as charcoal filtration,
where marked variation in yields result when the Canadian
intense and standard ISO values are compared.
SELECTION OF TOXICANTS
Data on comprehensive lists of toxicants measured in a
consistent manner using the modified intense smoking regimen
were available from three sources: a publication by Counts et
al,
11 which compares a set of international brands manufactured
by Philip Morris, a set of Canadian brands
12 reported by law to
Health Canada for the year 2004, and a set of Australian
brands
13 provided to the Australian Department of Health and
Ageing in the year 2001. The toxicants considered were confined
to the list of toxicants reported in these data sets, but they
represent most of the toxicants thought to play a major role in
smoke toxicity.
The list of toxicants was prioritised by considering the known
animal and human toxicity data for the compounds, toxicity
indices based on the concentration of the constituent times its
toxic potency factor, the variability of the toxicant across
brands, the potential for the toxicant to be lowered in cigarette
smoke with existing methods, and the need to have constitu-
ents that represent the different phases of smoke (gas and
particulate), different chemical classes, and toxicities that reflect
heart and lung disease as well as cancer. The most important
criterion for selecting compounds for regulation is the direct
toxicity evidence, but the toxicants were also compared by
Figure 1 Ratio of the toxicant yield per
mg nicotine for measurements using the
Health Canada (HC) intense method and
the Massachusetts Department of Public
Health (MDPH) method compared to the
International Standards Organization (ISO)
method. X Median MDPH value as a
fraction of the ISO median, % median HC
value as a fraction of the ISO median.
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plying the yields per mg nicotine of individual smoke toxicants
using the standard ISO machine smoking method with animal
carcinogenicity and non-cancer potency factors, as a modifica-
tion of the approach presented by Fowles and Dybing.
14 Table 2
is an example of these indices calculated for the International
set of Philip Morris brands.
11
There are obvious limitations to the methodology used here
for ranking individual cigarette smoke toxicants. Each measured
toxicant is treated individually, such that the possibility of
chemical interactions—either enhancing or inhibiting the
hazardous properties of the smoke—is not taken into account.
Further, it is obvious that these calculations have only been
possible for those toxicants where index values have been
estimated, and not for the rest of the some 4000 individual
constituents in cigarette smoke.
15 Since many of the potency
factors have been derived from animal experiments, the obvious
limitations in extrapolating from animal models to the human
situation also apply. These limitations preclude use of these
indices as quantitative estimates of the likely harm or risk of
exposure to these different toxicants or for comparison of the
relative risk or harm of different cigarette brands. They do,
however, provide one useful set of metrics that can be
considered in selecting which toxicants to regulate.
In addition to those toxicants recommended for mandatory
lowering, an additional set of toxicants were considered high
priority for disclosure and monitoring of their levels by brand.
They are: acrylonitrile, 4-aminobiphenhyl, 2-aminonaphtha-
lene, cadmium, catechol, crotonaldehyde, hydrogen cyanide,
hydroquinone, and nitrogen oxides.
Comparison of the mean levels of the specific toxicants across
the different data sets for different countries helps define the
differences in yield that result from the differences in the design
of cigarettes offered for sale in different markets. Figure 2
presents the mean levels of each toxicant per mg nicotine, across
all brands within the Canadian data set, the Canadian data set
minus the US and French brands and for the Australian data.
These means are presented as a ratio of the mean value for the
toxicant per mg nicotine in the specified data set to the mean
levels reported by Counts et al
11 for the international Philip
Morris brands. The magnitude of the variation in toxicant levels
between the data sets is as large as, and sometimes exceeds, the
variation in levels across brands within a data set. The
magnitude of these variations suggests that examination of
differences in toxicant yields for brands sold in different markets
can offer an expanded understanding of the levels of individual
toxicants potentially achievable with changes in cigarette design
and manufacturing practices.
THE BALANCE BETWEEN LEVELS, NUMBER OF TOXICANTS
AND REMOVAL FROM THE MARKET
In the absence of a change in cigarette manufacturing processes,
the number of brands potentially eliminated from the market
by the proposed regulatory approach is dependent on the levels
set and the number of toxicants regulated. Greater mandated
reductions are possible where there is a high level of confidence
that the levels of toxicants can be substantially reduced, as there
is for tobacco specific nitrosamines, or when only a few
toxicants are regulated. However, when only a few toxicants
are regulated there is a greater probability that reductions in one
toxicant might result in higher level of other toxicants in the
brands remaining on the market as an unintended consequence.
In considering this trade-off between numbers of toxicants
regulated, levels of mandated reduction and numbers of brands
eliminated from the market, TobReg felt that regulating a larger
number of toxicants at the expense of accepting more modest
levels of reductions reflected a more conservative initial step for
regulation. As experience is accumulated with the capacity of
the cigarette manufacturers to modify their products to achieve
lower yields of specific toxicants, more aggressive targets for
mandated lowering can be set by regulatory authorities.
USES OF MANDATED LOWERING OF TOXICANT LEVELS IN A
PRODUCT REGULATORY STRATEGY
The goal of the proposed regulatory strategy is to reduce the
levels of toxic constituents measured under standardised
conditions in the smoke of cigarettes allowed on the market.
A secondary goal is to prevent the introduction into a market of
cigarettes with higher levels of smoke toxicants than are present
in brands already on the market.
The value of examining the variation in toxicant yields for the
market of interest rather than using an international sample is
exemplified by comparing the benzo[a]pyrene yields in the
international sample with those reported to Health Canada for
Canadian brands (fig 3). When the international sample is ranked
from the brand with the lowest level of benzo[a]pyrene/mg
nicotine to the brand with the highest value, there is a
continuous steady increase across the brands from 5.7 ng/mg
nicotine to 13.8 ng/mg nicotine. By contrast, the ranking of
Canadian brands from the lowest to the highest values presented
in fig 3 reveals a level rising to approximately 9.6 ng/mg nicotine
with a sudden jump to 16.8 ng/mg nicotine. The explanation for
this sudden discontinuity in levels is not immediately evident,
but the value of examining the Canadian experience rather than
assuming that the sample of international brands would provide
an adequate description of the Canadian market for establishing
mandated reductions is evident.
The possibility exists that, in the absence of effective product
regulation, toxicant yields for the mix of brands on a market
may actually increase as new brands are introduced or the
characteristics of existing brands are changed. This possibility is
of particular concern for those markets where current levels of
toxicants are lower than those for brands sold in other markets.
The data presented in fig 4 demonstrate that the brands
reported to Health Canada with high NNK levels are largely
brands also sold in the US and France, rather than those brands
that are predominantly sold in the Canadian market. A similar
circumstance exists in Australia and is presented in fig 5. The
mean and range of NNN and NNK yields per mg nicotine for
the brands sold in Australia (including Philip Morris brands) and
reported to the Australian government in 2001
13 are presented in
the figure. They are contrasted with the much higher levels of
NNN and NNK reported for a Philip Morris Marlboro brand
identified as being an Australian brand in the paper by Counts
and colleagues.
11 To the extent that Marlboro becomes a leading
brand in the Australian market, as it has in many other markets,
the difference in NNN and NNK levels would be expected to
increase the average yield for these toxicants of the cigarettes on
the Australian market. Setting levels for toxicants would
provide a regulatory strategy that could prevent the introduc-
tion of newer brands with greater toxicant yields than the
existing brands.
MONITORING FOR UNINTENDED INCREASES IN TOXICANT
YIELDS
Mandating a reduction in some toxicants does not guarantee
that levels of other, non-regulated toxicants will also be
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for brands in different samples to the
mean of the Counts et al
11 sample.
Figure 3 Benzoapyrene yield per mg nicotine in Canadian brands.
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brands high in levels of the regulated toxicants will leave brands
on the market with high levels of those toxicants not regulated.
In addition, the changes in cigarette design and manufacturing
implemented to lower the regulated toxicants may have the
effect of increasing the levels of other non-regulated toxicants.
TobReg recognised the potential for these unintended con-
sequences of mandating reduction of specific toxicants and
considered how monitoring might be put in place to detect
them.
One approach would be to track the yields, or the percentage
change in median yields, for the entire list of toxicants measured
by Health Canada. However, different toxicants have different
potency as toxicants, and the range of toxicant per mg nicotine
(defining the amount of reduction possible with the proposed
regulatory approach) is also different for the different toxicants.
As a result, the net effect of a mandated reduction of some
toxicants on total toxicant burden of the brands remaining will
depend on the potency of the toxicant selected and the
magnitude of the reduction achieved.
Based on these considerations, TobReg recommends using the
sum of the individual toxicant animal carcinogenicity indices of
the brands remaining on the market as a tool for examining the
potential unintended consequences of regulation on net
toxicant yields. TobReg chose this approach as a means of
integrating animal toxicity data and toxicant level data of
smoke generated under standardised conditions for the purpose
of monitoring the effects of implementing the proposed
regulatory approach on net toxicant yields. The sum of the
toxicant animal carcinogenicity indices generated, and changes
in that index, are mathematical constructs of toxicant yields
and are based on animal toxicological evidence. They are not
quantitative estimates of the human toxicity of the smoke of
different brands or of the risk of developing cancer or other
diseases in humans from smoking different brands, and they
should not be applied in any quantitative way to estimating the
risk of smoking or the overall toxicity of the smoke generated.
They are recommended solely for use as a monitoring tool for
regulators.
CONSIDERATIONS FOR MODIFIED CIGARETTES AND
POTENTIAL REDUCED EXPOSURE PRODUCTS
The recommendations in this report are intended to apply to
traditional manufactured cigarettes that burn tobacco, and they
should not be applied to cigarettes that heat tobacco or use
technology other than combustion to deliver nicotine.
Assessment of these unconventional tobacco products and
other potential reduced exposure products (PREPs) are discussed
in a previous WHO Scientific Advisory Committee on Tobacco
Figure 4 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and N9-nitrosonornicotine (NNN) by brand for Canadian cigarettes.
Figure 5 Mean and range of 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone (NNK) and N9-nitrosonornicotine (NNN) yields per mg nicotine
for brands reported to the Australian government in 1999 contrasted with
the levels of NNN and NNK reported for a Philip Morris Marlboro brand
identified as being an Australian brand.
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3 It is possible to alter the
level of a toxicant per mg nicotine in cigarette smoke by
changing the nicotine yield of the cigarette, as well as by
altering the level of the toxicant. The yield of nicotine in
cigarette smoke can be increased by adding nicotine to the
tobacco or the filter, as well as by using high-nicotine varieties
of tobacco, among other approaches. While these approaches
may theoretically have independent utility in decreasing
exposure to tobacco toxicants, their potential to do so remains
uncertain. Detection of increasing nicotine yields in brands can
be facilitated by tracking of machine delivered nicotine yields
per cigarette over time and by examining the distribution of tar
to nicotine ratios for the brands within a given market. For
those brands with increasing nicotine yields over time, and for
those brands with tar to nicotine ratios in the bottom third of
the brands on the market, regulators may choose to require that
the brand be below a mandated limit value per mg tar as well as
per mg nicotine. A similar adjustment to use per mg tar values
can be made to those products that intentionally lower the
nicotine content of the product.
COMMUNICATION OF THE REGULATORY VALUES AND TESTING
RESULTS TO THE PUBLIC
The mandated reduction of toxicant levels recommended in this
report constitutes a first step toward improved tobacco product
regulation. TobReg recognises the limitations of machine
measurements and of setting levels based on per mg nicotine.
Existing science does not allow a definitive conclusion that
reduction of nitrosamines, or any other individual toxicants in
cigarette smoke, will reduce cancer incidence, or the rate of any
other tobacco related disease, in smokers who use cigarettes
with lower levels of these toxicants, even though this is a hoped
for outcome. Existing science has also not demonstrated that
the specified changes in regulatory values will result overall in a
meaningful change in actual exposure for consumers, although
that is also a hoped for outcome. Mandating levels and
disallowing brands with higher levels from the market is not a
statement that the remaining brands are safe or less hazardous
than the brands removed. It also does not represent govern-
mental validation of the safety of the products that remain on
the market. The proposed strategy for lowering toxicant yields
is based on sound precautionary approaches of reducing
toxicant levels where possible, similar to those used for other
chemical consumer products.
Given the limitations of existing science, regulatory autho-
rities have an obligation to ensure that the public is not misled
by the results of the recommended machine testing and
mandated lowering regulatory strategy, as the public was
misled by the use of machine testing for tar and nicotine yields.
TobReg notes that labelling of cigarettes with tar and nicotine
and carbon monoxide levels measured by the ISO regimen
persists and continues to be harmful to the public. TobReg
recommends that any regulatory approach specifically prohibit
the use of the results of the proposed testing in marketing or
other communications with the consuming public including
product labelling. It is also recommended that manufacturers be
prohibited from making statements that a brand has met
governmental regulatory standards, and from publicising the
relative ranking of brands by testing levels. Because information
is often transmitted to smokers through the kinds of news
stories that accompany new regulation implementation, it is a
responsibility of the regulatory structure to monitor the
understanding of the consumer about the regulatory approaches
undertaken. Regulators should pursue whatever corrective
action is necessary to prevent consumers from being misled.
SUMMARY
The WHO FCTC recognises the need for tobacco product
regulation. It is incongruous that cigarettes, the single most
hazardous consumer product, are not regulated as a product
consistent with that hazard. Existing product regulatory
strategies based on the machine measured tar, nicotine and
carbon monoxide yields per cigarette are causing harm.
Additional scientific research will be needed to develop validated
measures of human exposure and risk that can be applied to
individual brands; and, in the interim, performance standards
based on machine measured emissions may be the limit of
science-based regulation of individual brands. A strategy for
regulation is proposed by the WHO based on product
performance measures with the goal of reducing toxicant levels
in mainstream cigarette smoke. It recommends establishing
levels for selected smoke toxicants per mg nicotine and
prohibiting the sale or import of cigarette brands that have
yields above these levels. The toxicants selected were based on
consideration of: animal and human toxicity data, hazard
indices, variability of the toxicants across brands, the potential
for the toxicant to be lowered, inclusion of constituents from
both particulate and gas phases of smoke and from different
chemical classes in cigarette smoke. Available data on the
variation in the toxicant levels for cigarette brands are used to
identify levels of reduction that have already been achieved by
some products on the existing market. The recommended
regulatory strategy should be implemented in phases beginning
with a period of required annual reporting of followed by the
promulgation of the regulatory levels for toxicants above which
brands cannot be marketed and enforcement of those levels.
Mandated lowering of levels of toxicants per mg nicotine in
cigarette smoke will make regulation of cigarettes consistent
with other regulatory approaches which mandate reduction of
known toxicants in products used by humans. Use of the results
of the testing, or of relative ranking of brands by testing levels,
should be prohibited as are statements that the brand has met
governmental regulatory standards.
The views expressed here are those of the authors only and do not represent any
official position of the National Cancer Institute or the National Institutes of Health.
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